Randomized Crossover Comparison of Injection Site Pain with 40 mg/0.4 or 0.8 mL Formulations of Adalimumab in Patients with Rheumatoid Arthritis

INTRODUCTION: Adalimumab, an anti-tumor necrosis factor antibody, is currently available in a 40 mg/0.8 mL formulation. The objective of this analysis was to evaluate injection site-related pain, safety, and tolerability of a 40 mg/0.4 mL formulation of adalimumab that had fewer excipients, a smalle...

Descripción completa

Detalles Bibliográficos
Autores principales: Nash, Peter, Vanhoof, Johan, Hall, Stephen, Arulmani, Udayasankar, Tarzynski-Potempa, Rita, Unnebrink, Kristina, Payne, Andrew N., Cividino, Alfred
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5127965/
https://www.ncbi.nlm.nih.gov/pubmed/27747583
http://dx.doi.org/10.1007/s40744-016-0041-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5127965/
https://www.ncbi.nlm.nih.gov/pubmed/27747583
http://dx.doi.org/10.1007/s40744-016-0041-3

Ejemplares similares